

**BURSOR & FISHER, P.A.**

L. Timothy Fisher (State Bar No. 191626)  
Joel D. Smith (State Bar No. 244902)  
Sean L. Litteral (State Bar No. 331985)  
1990 North California Boulevard, Suite 940  
Walnut Creek, CA 94596  
Telephone: (925) 300-4455  
Facsimile: (925) 407-2700  
E-Mail: ltfisher@bursor.com  
jsmith@bursor.com  
slitteral@bursor.com

*Attorneys for Plaintiff*

**UNITED STATES DISTRICT COURT  
EASTERN DISTRICT OF CALIFORNIA**

VANESSA GONZALEZ, individually and on  
behalf of all others similarly situated,

Plaintiff,

v.

PERFORMIX LLC,

Defendant.

Case No.

**CLASS ACTION COMPLAINT**

JURY TRIAL DEMANDED

1 Plaintiff Vanessa Gonzalez (“Plaintiff”), individually and on behalf of all other similarly  
2 situated purchasers (hereafter the “Class”), brings this consumer class action against Performix  
3 LLC (“Defendant”) for the distribution, advertisement, and sale of dietary supplement capsules  
4 sold as SST Timed Release Metabolism (the “Product”) and alleges as follows:

5 **JURISDICTION AND VENUE**

6 1. This Court has subject matter jurisdiction pursuant to 28 U.S.C. § 1332(d)(2)(A)  
7 because this case is a class action where the aggregate claims of all members of the proposed  
8 class are in excess of \$5,000,000.00, exclusive of interest and costs, and members of the  
9 proposed class are citizens of states different from Defendant. This Court also has supplemental  
10 jurisdiction over state law claims pursuant to 28 U.S.C. § 1367.

11 2. Pursuant to 28 U.S.C. § 1391, this Court is the proper venue for this action  
12 because Plaintiff is a citizen of California and resides in this District, and because Plaintiff  
13 purchased her Product in this District. Moreover, Defendant distributed, advertised, and sold the  
14 Product, which is the subject of the present complaint, in this District.

15 **THE PARTIES**

16 3. Plaintiff Vanessa Gonzalez is an individual domiciled in Modesto, California. In  
17 January 2020, Plaintiff Gonzalez purchased SST Timed Release Metabolism from a GNC Store  
18 located in Modesto, California. She purchased these capsules for herself. In doing so, Plaintiff  
19 Gonzalez relied upon Defendant’s advertising, packaging, labeling and other promotional  
20 materials, which were jointly prepared and approved by Defendant and its agents and disseminated  
21 through advertising media containing the misrepresentations, concealments and unlawful claims  
22 alleged herein. Plaintiff Gonzalez would not have purchased Defendant’s capsules if she had  
23 known that they were unlawful to sell under California law.

24 4. Defendant Performix LLC is a Colorado company with its principal place of  
25 business in New York, New York. At times relevant to this Complaint, Defendant has advertised,  
26 marketed, and sold a variety of cosmetic products, including that at issue, to consumers throughout  
27 the United States and the State of California. Defendant has sold the Product directly to consumers  
28 via the Internet and through third-party retail stores throughout the United States, including in this

1 District.

2 **FACTUAL ALLEGATIONS**

3 **The Labelling Requirements for Dietary Supplements**

4 5. In 2020, the dietary supplements market in the U.S. was estimated at \$46 Billion,  
5 and the global market for dietary supplements is expected to grow to \$298.5 Billion by 2027.<sup>1</sup>

6 6. For decades, consumers have been prioritizing their health and wellness through the  
7 use of dietary supplements. That interest took on even greater resonance when the COVID-19  
8 pandemic struck last year, with millions of American consumers seeking out ways to stay healthy  
9 and boost their immunity.

10 7. According to leading market research firm IRI, spurred by the pandemic, the  
11 vitamin and supplement category has skyrocketed. IRI calculates that vitamin, mineral and  
12 supplement sales have risen 21% since the pandemic began, with market shares of certain types of  
13 vitamins and supplements increasing exponentially. Crowe, Emily, Behind the growth in the  
14 dietary supplement, vitamin market. *Smart Brief* (March 3, 2021) (accessible at:  
15 <https://www.smartbrief.com/original/2021/03/behind-growth-dietary-supplement-vitamin-market>).

16 8. Larry Levin, executive vice president of consumer and shopper marketing at IRI  
17 states that: “Prior to COVID-19, 80% of consumers were using vitamins, minerals and supplements  
18 as part of their ritual anyway, but I think the pandemic just strengthened their commitment to the  
19 product category.” *Id.*

20 9. IRI data shows that buying vitamins and supplements has been at the forefront of  
21 consumers’ minds since the early days of the pandemic, with 35% of households buying vitamins  
22 in the four weeks ending April 5, 2020. *Id.* The momentum has continued, with 40.6 million  
23 households purchasing vitamins in January 2021, compared to 35.5 million the prior year.  
24 According to Mr. Levin, “When you think about the impact that category has on our lifestyle, it’s  
25 really profound.” *Id.*

26 \_\_\_\_\_  
27 <sup>1</sup> <https://www.businesswire.com/news/home/20210219005385/en/Global-Dietary-Supplements-Market-Report-2020-Market-to-Reach-298.5-Billion-by-2027---U.S.-Market-is-Estimated-at-46-Billion-While-China-is-Forecast-to-Grow-at-12.7-CAGR---ResearchAndMarkets.com>.  
28

1           10.     The COVID-19 pandemic has demonstrated more than ever that consumers will  
2 seek to support their health through dietary supplements and, in making those critical purchasing  
3 decisions, must be able to trust that labels and claims for dietary supplements are truthful,  
4 substantiated, and meet all legal requirements to be lawfully sold over the counter.

5           11.     The Federal Food, Drug, and Cosmetic Act of 1938, 21 U.S.C. § 301 *et seq.* (the  
6 “FFDCA” or the “Act”), as amended by the Dietary Supplement Health and Education Act of  
7 1994, Pub. L. No. 103–417, 108 Stat. 4325 (“DSHEA”), as well as the regulations implementing  
8 the FFDCA and DSHEA set forth the legal requirements for labelling and selling dietary  
9 supplements. These requirements are fully incorporated into California’s Sherman Food, Drug,  
10 and Cosmetic Law, Cal. Health & Safety Code § 109875 *et seq.* (“Sherman Law”).

11           12.     Under the FFDCA, a “drug” is defined, in part, as an “article[] intended for use in  
12 the diagnosis, cure, mitigation, treatment, or prevention of disease in man or other animals” or an  
13 “article[] (other than food) intended to affect the structure or any function of the body of man or  
14 other animals.”

15           13.     Under 21 U.S.C. §§ 331(d) and 355(a), the FDA must approve new drugs before  
16 they can be sold on the market. The FFDCA creates an exemption from this pre-approval process  
17 for dietary supplements “intended to affect the structure or function of the body” if the dietary  
18 supplements carry a prominent FDA disclaimer on the product labels and advertising.

19           14.     Under these regulations, supplement companies like Defendant are prohibited from  
20 labeling, marketing, or selling dietary supplements bearing claims that “describe[] the role of a  
21 nutrient or dietary ingredient intended to affect the structure or function in humans, [or that]  
22 characterize[] the documented mechanism by which a nutrient or dietary ingredient acts to  
23 maintain such structure or function” (known as “structure/function claims”), unless the label carries  
24 a prominent disclaimer (the “DSHEA Disclaimer”) on each panel bearing such claims. *See* 21  
25 U.S.C. §§ 321(g)(1), 331(d), 343(r)(1)(B), 343(r)(6), 355(a); 21 C.F.R. § 101.93(d) (“On product  
26 labels and in labeling (e.g., pamphlets, catalogs), the disclaimer shall appear on each panel or page  
27 where there [is a structure/function claim].”).

28           15.     The DSHEA Disclaimer must be prominent and bolded, and it must read:

1                   **These statements have not been evaluated by the Food and Drug**  
2                   **Administration. This product is not intended to diagnose, treat,**  
3                   **cure, or prevent any disease.**

21 U.S.C. § 343(r)(6)(C); *see also* 21 C.F.R. § 101.93(b)-(e).

4           16.     As one Court recently explained, the DSHEA Disclaimer requirement is important  
5 for consumer safety:

6                   The disclaimer requirement aligns with the FDA’s recognition that  
7                   few dietary supplements have been the subjects of adequately  
8                   designed clinical trials. Without the disclaimer, structure/function  
9                   claims convey therapeutic drug claims, thereby encouraging self-  
10                  treatment without the benefit of a medical diagnosis or treatment.  
11                  The point of the disclaimers are to make sure that consumers  
12                  understand that structure/function claims are not reviewed by [the]  
13                  FDA prior to marketing, and to caution consumers that dietary  
14                  supplements bearing such claims are not for therapeutic uses.

11           *Arora v. GNC Holdings, Inc.*, No. 19-cv-02414-LB, 2019 WL 6050750, at \*3 (N.D. Cal. Nov. 15,  
12 2019) (internal quotation marks and citations omitted) (emphasis in original).

13           17.     Dietary supplements that do not bear the required DSHEA Disclaimer on **all** panels  
14 with structure/function claims, and/or the disclaimer lacks the prominence required, are  
15 misbranded and unlawful. 21 U.S.C. § 343(r)(1)(B), (r)(6); 21 C.F.R. § 101.93(d).

16           18.     Moreover, such products qualify as “drugs” under the FFDCa because they are  
17 marketed with structure/function claims but do not include the DSHEA Disclaimer. *See* 21 U.S.C.  
18 §§321(g)(1), 343(r)(6). To avoid being regulated as drugs under the FFDCa, dietary supplements  
19 bearing structure/function claims must comply with the DSHEA Disclaimer requirements. *Id.*


20           19.     Misbranded dietary supplements and/or unapproved drugs are unlawful and cannot  
21 be sold legally under federal and identical California law. 21 U.S.C. §§ 331, 333.

22           **Defendant Performix LLC’s Unlawful Advertising, Sale and Labeling of the Product**

23           20.     Unfortunately for consumers, Defendant Performix LLC continues to advertise, sell,  
24 and label its product in violation of the statutes referred to herein.

25           21.     In or around January 2020, Plaintiff purchased Defendant Performix LLC’s  
26 vitamins. However, as the photograph below demonstrates, Defendant’s Product does not comply  
27 with the laws and regulations set out herein.

1           22. The left-facing panel (of which clear photos are not readily available) of  
2 Defendant’s SST Timed Release Metabolism explicitly states under the heading “ENERGY AND  
3 METABOLISM,” that “*Performix SST is powered by Caffeine and Capsimax to accelerate your*  
4 *body’s metabolism, provide sustained energy, and support fat breakdown.*” (emphasis added).  
5 Defendant also mentions that “*The inclusion of clinically-tested Capsimax, a naturally-derived,*  
6 *highly active concentrate of natural capsaicin which has been shown to increase resting energy*  
7 *expenditure by about 100 calories a day, allows Performix SST to accelerate your own body’s*  
8 *metabolism to provide energy.*” (emphasis added). Defendant further mentions, under the heading  
9 “FOCUS,” that “*Performix SST is powered by Caffeine, Teacrine, and Sensoril to promote*  
10 *focus, clarity, concentration, and alertness.*” (emphasis added). Each of these statements  
11 constitutes a structure/function claim. However, none of these statements are accompanied by the  
12 requisite DSHEA Disclaimer on that panel.



1 **Plaintiff's Purchase of the Product**

2 23. Plaintiff purchased the Product during the relevant class period. Prior to purchasing  
3 the Product, Plaintiff saw, heard, and relied upon packaging, labeling, advertisements,  
4 representations and statements made by Defendant, including advertisements and labels set forth  
5 above.

6 24. As a result of Defendant's representations, sale, and offer for sale, of the Product,  
7 Plaintiff believed that the Product was lawful, correctly branded, subject to a governmental review  
8 and approval process, and had therapeutic value, including that they were intended to prevent or  
9 treat disease.

10 25. Plaintiff has suffered injury in fact and lost money as a result of Defendant's  
11 conduct described herein. Plaintiff would not have purchased the Product had she known that the  
12 Product was unlawful to sell. Plaintiff otherwise paid more for the Product than had she known the  
13 truth about it and that it was unlawful to sell.

14 26. If Plaintiff was confident that the marketing and sale of the Product was lawful,  
15 truthful, and non-misleading, Plaintiff may purchase the Product in the future. At present,  
16 however, Plaintiff cannot purchase the Product because Plaintiff cannot be confident that it is  
17 lawful and that its labeling is truthful and non-misleading.

18 27. On July 16, 2021, Plaintiff issued a pre-suit demand for corrective action to  
19 Defendant, notifying it of its violations of California law. *See* Exhibit A. Defendant refused to  
20 repair or correct its violations, thus requiring Plaintiff to file this action.

21 **CLASS ACTION ALLEGATIONS**

22 28. Class Definition: Plaintiff brings this class action on behalf of herself, and as a class  
23 action on behalf of the following putative classes (the "Class"):

24 **Nationwide Class**

25 All individual residents of the United States who purchased the Product through the date of  
26 class certification. Excluded from the Class are: (1) Defendant and all directors, officers,  
27 employees, partners, principals, shareholders and agents of Defendant; (2) Any currently  
28 sitting United States District Court Judge or Justice, and the current spouse and all other



1 persons within the third-degree of consanguinity to such judge/justice; and (3) Class  
2 Counsel.

3 **California Sub-Class**

4 All individual residents of the State of California who purchased the Product through the  
5 date of class certification. Excluded from the Class are: (1) Defendant and all directors,  
6 officers, employees, partners, principals, shareholders and agents of Defendant; (2) Any  
7 currently sitting United States District Court Judge or Justice, and the current spouse and all  
8 other persons within the third-degree of consanguinity to such judge/justice; and (3) Class  
9 Counsel.

10 29. Plaintiff reserves the right to amend the Class definitions if further investigation and  
11 discovery indicates that the Class definitions should be narrowed, expanded, or otherwise  
12 modified.

13 30. Numerosity and Ascertainability: Plaintiff does not know the exact number of  
14 members of the putative classes. Due to Plaintiff's initial investigation, however, Plaintiff is  
15 informed and believes that the total number of Class members is at least in the tens of thousands,  
16 and that members of the Class are numerous and geographically dispersed throughout the United  
17 States and California. While the exact number and identities of the Class members are unknown at  
18 this time, such information can be ascertained through appropriate investigation and discovery,  
19 including Defendant's records, either manually or through computerized searches.

20 31. Typicality and Adequacy: Plaintiff's claims are typical of those of the proposed  
21 Class, and Plaintiff will fairly and adequately represent and protect the interests of the proposed  
22 Class. Plaintiff does not have any interests that are antagonistic to those of the proposed Class.  
23 Plaintiff has retained counsel competent and experienced in the prosecution of this type of  
24 litigation.

25 32. Commonality: The questions of law and fact common to the Class members, some  
26 of which are set out below, predominate over any questions affecting only individual Class  
27 members:

28 a. whether Defendant committed the conduct alleged herein;



- b. whether Defendant's conduct constitutes the violations of laws alleged herein;
- c. whether Defendant's labeling, sale and advertising set herein are unlawful, untrue, or are misleading, or reasonably likely to deceive;
- d. whether the Product are adulterated and/or misbranded under the California Health & Safety Code and identical federal law;
- e. whether Defendant knew or should have known that the representations were false or misleading;
- f. whether Defendant knowingly concealed or misrepresented material facts for the purpose of inducing consumers into spending money on the Product;
- g. whether Defendant's representations, concealments and non-disclosures concerning the Product are likely to deceive the consumer;
- h. whether Defendant's representations, concealments and non-disclosures concerning the Product violate the UCL and/or the common law;
- i. whether Defendant should be permanently enjoined from making the claims at issue; and
- j. whether Plaintiff and the Class are entitled to restitution and damages.

33. Predominance and Superiority: Common questions, some of which are set out above, predominate over any questions affecting only individual Class members. A class action is the superior method for the fair and just adjudication of this controversy. The expense and burden of individual suits makes it impossible and impracticable for members of the proposed Class to prosecute their claims individually and multiplies the burden on the judicial system presented by the complex legal and factual issues of this case. Individualized litigation also presents a potential for inconsistent or contradictory judgments. In contrast, the class action device presents far fewer management difficulties and provides the benefits of single adjudication, economy of scale, and comprehensive supervision by a single court on the issue of Defendant's liability. Class treatment of the liability issues will ensure that all claims and claimants are before this Court for consistent adjudication of the liability issues.



1 including, at least, the following sections: 21 C.F.R. § 101.93(b); 21 U.S.C. § 403(r)(6)(C); 21  
2 U.S.C. § 343(r)(6); and 21 U.S.C. §§ 331, 333.

3 42. As alleged herein, Defendant's conduct, including the above violations, violates the  
4 provisions of the California Sherman Food, Drug, and Cosmetic Law, Cal. Health & Safety Code §  
5 109875 et seq. (the "Sherman Law"), including, but not limited to, the following sections: §  
6 110100; § 110395; § 110398; § 110400.

7 43. In addition, Defendant has committed unlawful business practices by, *inter alia*,  
8 making the representations and omissions of material facts, as set forth more fully herein, and  
9 violating California Business & Professions Code § 17500, et seq., and the common law.

10 44. In addition, Defendant has unlawfully manufactured, advertised, and disseminated  
11 false advertisements of the Product, and that the product advertising and packaging contain false or  
12 misleading statements about the Product in violation of Bus. & Prof. Code § 17500 which govern  
13 Defendant's conduct.

14 45. Plaintiff and the California Sub-Class reserve the right to allege other violations of  
15 law which constitute other unlawful business acts or practices. Such conduct is ongoing and  
16 continues to this date.

17 46. **Unfair Business Practices:** California Business & Professions Code § 17200 also  
18 prohibits any "unfair ... business act or practice."

19 47. Defendant's acts, omissions, misrepresentations, practices and non-disclosures as  
20 alleged herein also constitute "unfair" business acts and practices within the meaning of Business  
21 & Professions Code § 17200 *et seq.* in that its conduct is substantially injurious to consumers,  
22 offends public policy, and is immoral, unethical, oppressive, and unscrupulous as the gravity of the  
23 conduct outweighs any alleged benefits attributable to such conduct.

24 48. There were reasonably available alternatives to further Defendant's legitimate  
25 business interests, other than the conduct described herein.

26 49. Pursuant to section 17203 of the California Business & Professions Code, Plaintiff  
27 and the California Sub-Class seek an order of this court enjoining Defendant from continuing to  
28 engage in unlawful and unfair business practices and any other act prohibited by law, including,

1 but not limited to: (a) selling, marketing, or advertising the Product with representations set forth  
2 above; (b) engaging in any of the illegal, misleading, unlawful and/or unfair conduct described  
3 herein; and (c) engaging in any other conduct found by the Court to be illegal, misleading,  
4 unlawful, and/or unfair conduct.

5 50. In addition, Plaintiff requests that this Court enter such orders or judgments as may  
6 be necessary to restore to any person in interest any money which may have been acquired by  
7 means of such illegal practices as provided in Business & Professions Code § 17203, and for such  
8 other relief as set forth below.

9 51. Plaintiff engaged counsel to prosecute this action and is entitled to recover costs and  
10 reasonable attorney's fees according to proof at trial.

11 **SECOND CAUSE OF ACTION**  
12 **UNJUST ENRICHMENT**

13 76. Plaintiff incorporates by this reference the allegations contained in the preceding  
14 paragraphs as if fully set forth herein.

15 77. Plaintiff brings this claim individually and on behalf of the proposed Class against  
16 Defendant.

17 78. As a result of Defendant's unlawful and misleading labeling, marketing, and sale of  
18 the Product, Defendant was enriched at the expense of Plaintiff.

19 79. Defendant sold Product to Plaintiff that was not capable of being sold legally and  
20 that was worthless.

21 80. Plaintiff paid a premium price for the Product.

22 81. Thus, it is against equity and good conscience to permit Defendant to retain the ill-  
23 gotten benefits received from Plaintiff and the Nationwide Subclass members given that the  
24 Product was not what Defendant purported it to be.

25 82. It would be unjust and inequitable for Defendant to retain the benefit, warranting  
26 restitutionary disgorgement to Plaintiff and Class members of all monies paid for the Product,  
27 and/or all monies paid for which Plaintiff and the Class members did not receive benefit.

28 83. As a direct and proximate result of Defendant's actions, Plaintiff and Class

1 members have suffered damages in an amount to be proven at trial.

2 **PRAYER FOR RELIEF**

3 WHEREFORE, Plaintiff, on behalf of herself and as representative of all other persons  
4 similarly situated, prays for judgment against Defendant, as follows:

5 1. An order certifying that the action may be maintained as a Class Action under Fed.  
6 R. Civ. P. 23;

7 2. An order permanently enjoining Defendant from pursuing the policies, acts, and  
8 practices complained of herein;

9 3. An order requiring Defendant to pay restitution to Plaintiff and all members of the  
10 Class;

11 4. An order requiring Defendant to pay damages to Plaintiff and all members of the  
12 Class;

13 5. An order requiring Defendant to pay punitive damages to Plaintiff and all members  
14 of the Class;

15 6. For pre-judgment interest from the date of filing this suit;

16 7. For reasonable attorneys' fees;

17 8. Costs of this suit; and,

18 9. Such other and further relief as the Court may deem necessary and appropriate.

19 **DEMAND FOR JURY TRIAL**

20 Plaintiff hereby demands a jury trial on all issues so triable.

21 Dated: August 20, 2021

22 Respectfully submitted,

23 **BURSOR & FISHER, P.A.**

24 By:                   /s/ L. Timothy Fisher                  

25 L. Timothy Fisher (State Bar No. 191626)  
26 Joel D. Smith (State Bar No. 244902)  
27 Sean L. Litteral (State Bar No. 331985)  
28 1990 North California Boulevard, Suite 940  
Walnut Creek, CA 94596

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

Telephone: (925) 300-4455  
Facsimile: (925) 407-2700  
E-Mail: ltfisher@bursor.com  
jsmith@bursor.com  
slitteral@bursor.com

*Attorneys for Plaintiff*

CIVIL COVER SHEET

The JS 44 civil cover sheet and the information contained herein neither replace nor supplement the filing and service of pleadings or other papers as required by law, except as provided by local rules of court. This form, approved by the Judicial Conference of the United States in September 1974, is required for the use of the Clerk of Court for the purpose of initiating the civil docket sheet. (SEE INSTRUCTIONS ON NEXT PAGE OF THIS FORM.)

I. (a) PLAINTIFFS

VANESSA GONZALEZ, individually and on behalf of all others similarly situated

(b) County of Residence of First Listed Plaintiff Stanislaus (EXCEPT IN U.S. PLAINTIFF CASES)

(c) Attorneys (Firm Name, Address, and Telephone Number) Bursor & Fisher, P.A. L. Timothy Fisher 1990 N. California Blvd., Suite 940 Walnut Creek, CA 94596

DEFENDANTS

PERFORMIX, LLC

County of Residence of First Listed Defendant (IN U.S. PLAINTIFF CASES ONLY)

NOTE: IN LAND CONDEMNATION CASES, USE THE LOCATION OF THE TRACT OF LAND INVOLVED.

Attorneys (If Known)

II. BASIS OF JURISDICTION (Place an "X" in One Box Only)

- 1 U.S. Government Plaintiff, 2 U.S. Government Defendant, 3 Federal Question (U.S. Government Not a Party), 4 Diversity (Indicate Citizenship of Parties in Item III)

III. CITIZENSHIP OF PRINCIPAL PARTIES (Place an "X" in One Box for Plaintiff and One Box for Defendant)

- Citizen of This State, Citizen of Another State, Citizen or Subject of a Foreign Country, PTF DEF, 1 1, 2 2, 3 3, 4 4, 5 5, 6 6

IV. NATURE OF SUIT (Place an "X" in One Box Only)

Click here for: Nature of Suit Code Descriptions.

Table with 5 columns: CONTRACT, REAL PROPERTY, TORTS, CIVIL RIGHTS, PRISONER PETITIONS, FORFEITURE/PENALTY, LABOR, IMMIGRATION, BANKRUPTCY, SOCIAL SECURITY, FEDERAL TAX SUITS, OTHER STATUTES. Includes various legal categories like Personal Injury, Property Damage, Labor, etc.

V. ORIGIN (Place an "X" in One Box Only)

- 1 Original Proceeding, 2 Removed from State Court, 3 Remanded from Appellate Court, 4 Reinstated or Reopened, 5 Transferred from Another District, 6 Multidistrict Litigation - Transfer, 8 Multidistrict Litigation - Direct File

VI. CAUSE OF ACTION

Cite the U.S. Civil Statute under which you are filing (Do not cite jurisdictional statutes unless diversity): 28 U.S.C. § 1332. Brief description of cause: Failure to comply with FDA labeling requirements.

VII. REQUESTED IN COMPLAINT:

CHECK IF THIS IS A CLASS ACTION UNDER RULE 23, F.R.Cv.P. DEMAND \$ CHECK YES only if demanded in complaint: JURY DEMAND: Yes No

VIII. RELATED CASE(S) IF ANY

(See instructions): JUDGE DOCKET NUMBER

DATE 8/20/2021 SIGNATURE OF ATTORNEY OF RECORD /s/ L. Timothy Fisher

FOR OFFICE USE ONLY: RECEIPT #, AMOUNT, APPLYING IFP, JUDGE, MAG. JUDGE